ADMA Biologics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADMA research report →
Companywww.admabiologics.com
ADMA Biologics, Inc. , a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
- CEO
- Adam S. Grossman
- IPO
- 2013
- Employees
- 685
- HQ
- Ramsey, NJ, US
Price Chart
Valuation
- Market Cap
- $1.98B
- P/E
- 12.22
- P/S
- 3.89
- P/B
- 5.18
- EV/EBITDA
- 9.64
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 61.27%
- Op Margin
- 40.57%
- Net Margin
- 32.43%
- ROE
- 38.97%
- ROIC
- 27.81%
Growth & Income
- Revenue
- $510.17M · 19.63%
- Net Income
- $146.93M · -25.67%
- EPS
- $0.62 · -27.06%
- Op Income
- $191.44M
- FCF YoY
- -74.73%
Performance & Tape
- 52W High
- $22.37
- 52W Low
- $7.21
- 50D MA
- $10.83
- 200D MA
- $15.29
- Beta
- 0.82
- Avg Volume
- 7.31M
Get TickerSpark's AI analysis on ADMA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Grossman Jerrold B | buy | 12,500 |
| May 11, 26 | Grossman Jerrold B | buy | 12,500 |
| Apr 1, 26 | Kestenberg-Messina Kaitlin M. | other | 20,362 |
| Mar 13, 26 | Guiheen Lawrence P. | other | 30,000 |
| Mar 17, 26 | Guiheen Lawrence P. | other | 30,000 |
| Mar 17, 26 | Guiheen Lawrence P. | other | 30,000 |
| Mar 13, 26 | Guiheen Lawrence P. | other | 30,000 |
| Mar 16, 26 | Grossman Adam S | other | 15,000 |
| Mar 16, 26 | Grossman Adam S | sell | 15,000 |
| Mar 16, 26 | Grossman Adam S | sell | 6,000 |
Our ADMA Coverage
We haven't published any research on ADMA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ADMA Report →